In particular, gene sets related to E2F, G2M and MYC targets emerge as upregulated, while gene sets related to antibody recognition such as gamma-interferon responses, EMT, allograft rejection emerge as downregulated, suggesting that CTCs are immune-evading tumor cells. The gene discussed is MYC; the disease is neoplasm.